Multiple Myeloma × Genitourinary × Clear all
NCT04314401 2026-03-18

National Cancer Institute "Cancer Moonshot Biobank"

National Cancer Institute (NCI)

Recruiting
1,600 enrolled
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
NCT02012699 2026-01-22

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled
NCT05366881 2026-01-20

CAMPERR

Adela, Inc

Recruiting
7,000 enrolled
NCT07285044 2025-12-22

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Mayo Clinic

Phase 2 Recruiting
27 enrolled
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
NCT05131815 2025-02-26

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

Cedars-Sinai Medical Center

Phase NA Completed
8 enrolled
NCT06787807 2025-01-22

Proteomic Analysis of Patients Undergoing Bariatric Surgery

Universidade Federal de Pernambuco

Phase NA Not yet recruiting
103 enrolled
NCT04604158 2024-05-21

Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients

Cedars-Sinai Medical Center

Phase NA Completed
38 enrolled
NCT02333604 2024-04-15

CER

Cancer Support Community, Research and Training Institute, Philadelphia

Recruiting
15,000 enrolled
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
NCT01272817 2022-11-23

Mini-allo

Scripps Health

Phase NA Completed
36 enrolled
NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Celgene

Completed
1,149 enrolled
NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
NCT00006251 2020-01-21

Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Completed
21 enrolled
NCT00078858 2020-01-18

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Fred Hutchinson Cancer Center

Phase 1/2 Completed
37 enrolled
NCT03099031 2019-12-16

PREDICARE

LEO Pharma

Completed
420 enrolled
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
NCT00651716 2019-11-15

T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Vanderbilt-Ingram Cancer Center

Terminated
150 enrolled
NCT01159067 2019-06-18

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

City of Hope Medical Center

Phase 2 Terminated
1 enrolled 4 charts
NCT02900248 2019-04-02

N1

CureOne

Terminated
23 enrolled
NCT00896454 2018-10-17

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Amgen

Phase 2 Completed
33 enrolled 22 charts
NCT00949052 2018-08-16

Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

Vanderbilt-Ingram Cancer Center

Terminated
1,000 enrolled
NCT01484015 2018-07-18

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Wake Forest University Health Sciences

Phase 1 Completed
70 enrolled
NCT00617929 2017-12-28

Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
12 enrolled 12 charts